Connect your AI

Organon OGN Total Current Liabilities

Total Current Liabilities at other companies

PfizerPFE

$34.35B-5.8%

AmgenAMGN

$24.96B+8.5%

The Cooper Companies, Inc.COO

$1.8B+78.2%

BiogenBIIB

$3B-43.4%

AbbVieABBV

$42.1B+15.6%

Amneal Pharmaceuticals, Inc.AMRX

$728.05M-32.3%

Other financials

Income statement

Revenue$1.5B-3.5%

Gross profit$783.0M-6.9%

Net income$146.0M+67.8%

EPS (diluted)$0.55+66.7%

Balance sheet

Cash & equivalents$1.1B+104%

Total debt$8.6B-4.3%

Total equity$903.0M+66.6%

Total assets$13.0B-1.2%

Cash flow

Operating cash flow$225.0M+200%

CapEx$37.0M+15.6%

Free cash flow$188.0M+337%

Valuation

Market cap$3.53B-59.4%

Enterprise value$10.98B-26.4%

P/E6.6×+2.1×

P/S0.6×-0.8×

Profitability

Gross margin52.8%-4.4pp

Net margin8%-12.3pp

FCF margin11.1%-1.3pp

Returns & leverage

Return on equity71.6%—

Debt / equity9.5×-7.0×

Current ratio2×+0.3×

Where this comes from

Reported directly by Organon in its filing.

Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.

The official record: Organon’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Organon's total current liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Organon's total current liabilities?: Organon (OGN) reported total current liabilities of $2.5B in Q1 2026.
How has Organon's total current liabilities changed year-over-year?: Organon's total current liabilities decreased by 4.4% year-over-year, from $2.62B to $2.5B.
What is the long-term trend for Organon's total current liabilities?: Over 5 years (2020 to 2025), Organon's total current liabilities has grown at a -2.2% compound annual growth rate (CAGR), from $2.67B to $2.39B.
What does total current liabilities mean?: The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.